Facchini M, Muntwyler J, Schuiki E, Rickli H, Kiowski W, Amann F W
Abteilung Kardiologie, Universitätsspital Zürich.
Schweiz Med Wochenschr. 1998 Jan 17;128(3):72-9.
The clinical benefit of coronary stenting is reduced by the risk of thrombotic stent occlusion as well as hemorrhagic complications of intensive antithrombotic therapy. We compared the influence of different antithrombotic therapies on the incidence of post-interventional complications and in-hospital stay duration.
After successful placement of a coronary stent, 334 consecutive patients were given different antithrombotic treatments in addition to aspirin 100 mg/d indefinitely: (1) phenprocoumon for 3 months (n = 47), (2) low molecular weight heparin 2 x 100 U/kg/d s.c. for 4 weeks (n = 90), (3) ticlopidine 2 x 250 mg/d and low molecular weight heparin 2 x 100 U/kg/d s.c. for 4 weeks (n = 72) and (4) ticlopidine 2 x 250 mg/d for 4 weeks (n = 125).
Major events were subacute stent thrombosis in 17 patients (5%), and severe hemorrhagic complication in 20 patients (5.9%). The incidence of subacute stent thrombosis in groups 1 to 4 was 10.6%, 11%, 1.4% and 0.8% respectively. The use of ticlopidine was associated with a significant lowering of stent occlusions in univariate and multivariate analysis (p = 0.0013). Additional uni- and multivariate predictors were stent placement as a "bail-out" procedure (p = 0.033) and in patients with acute coronary syndrome (p = 0.049). Anticoagulant therapy was associated with a higher incidence of severe hemorrhagic complications (p < 0.01) and a prolonged in-hospital stay (p = 0.01).
These results confirm that anti-thrombotic therapy with aspirin and ticlopidine combines low rates of subacute stent occlusion and hemorrhagic complications. Treatment with phenprocoumon and low molecular weight heparin does not improve the rate of subacute stent occlusion but increases hemorrhagic complications. Very low rates of stent occlusion permit short in-hospital stays with concomitant reduction in cost.
冠状动脉支架置入术的临床益处因血栓形成导致支架闭塞的风险以及强化抗栓治疗的出血并发症而降低。我们比较了不同抗栓治疗对介入后并发症发生率和住院时间的影响。
在成功置入冠状动脉支架后,334例连续患者除了无限期服用100mg/d阿司匹林外,还接受了不同的抗栓治疗:(1)苯丙香豆素治疗3个月(n = 47),(2)低分子量肝素2×100U/kg/d皮下注射4周(n = 90),(3)噻氯匹定2×250mg/d加低分子量肝素2×100U/kg/d皮下注射4周(n = 72),以及(4)噻氯匹定2×250mg/d治疗4周(n = 125)。
主要事件为17例患者(5%)发生亚急性支架血栓形成,20例患者(5.9%)出现严重出血并发症。1至4组亚急性支架血栓形成的发生率分别为10.6%、11%、1.4%和0.8%。在单因素和多因素分析中,使用噻氯匹定与支架闭塞率显著降低相关(p = 0.0013)。其他单因素和多因素预测因素包括作为“补救”程序的支架置入(p = 0.033)以及急性冠状动脉综合征患者(p = 0.049)。抗凝治疗与严重出血并发症的较高发生率相关(p < 0.01)以及住院时间延长(p = 0.01)。
这些结果证实,阿司匹林和噻氯匹定联合抗栓治疗亚急性支架闭塞率和出血并发症发生率较低。苯丙香豆素和低分子量肝素治疗不能提高亚急性支架闭塞率,但会增加出血并发症。极低的支架闭塞率允许缩短住院时间并降低成本。